| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/27/2023 | 14.75% | Oppenheimer | $610 → $590 | Maintains | Outperform |
| 05/01/2023 | 18.64% | RBC Capital | $587 → $610 | Maintains | Outperform |
| 04/28/2023 | 18.64% | Oppenheimer | $580 → $610 | Maintains | Outperform |
| 02/27/2023 | 14.17% | RBC Capital | $545 → $587 | Maintains | Outperform |
| 11/03/2022 | 6% | RBC Capital | $541 → $545 | Maintains | Outperform |
| 08/01/2022 | 5.22% | RBC Capital | $592 → $541 | Maintains | Outperform |
| 04/28/2022 | 15.14% | RBC Capital | $579 → $592 | Maintains | Outperform |
| 03/04/2022 | 12.62% | RBC Capital | $609 → $579 | Maintains | Outperform |
| 07/29/2021 | 18.45% | RBC Capital | $604 → $609 | Maintains | Outperform |
| 02/25/2021 | 12.81% | Oppenheimer | $600 → $580 | Maintains | Outperform |
| 03/11/2020 | 4.06% | RBC Capital | $448 → $535 | Upgrades | Sector Perform → Outperform |
| 02/19/2020 | 4.06% | Oppenheimer | $525 → $535 | Maintains | Outperform |
| 11/25/2019 | -8.59% | Oppenheimer | $440 → $470 | Maintains | Perform |
| 11/01/2019 | -4.7% | JMP Securities | → $490 | Upgrades | Market Perform → Market Outperform |
| 02/25/2019 | -38.15% | RBC Capital | $313 → $318 | Maintains | Sector Perform |
| 10/12/2018 | -24.15% | B of A Securities | → $390 | Initiates Coverage On | → Buy |
What is the target price for Chemed (CHE)?
The latest price target for Chemed (NYSE: CHE) was reported by Oppenheimer on July 27, 2023. The analyst firm set a price target for $590.00 expecting CHE to rise to within 12 months (a possible 14.75% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Chemed (CHE)?
The latest analyst rating for Chemed (NYSE: CHE) was provided by Oppenheimer, and Chemed maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Chemed (CHE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemed was filed on July 27, 2023 so you should expect the next rating to be made available sometime around July 27, 2024.
Is the Analyst Rating Chemed (CHE) correct?
While ratings are subjective and will change, the latest Chemed (CHE) rating was a maintained with a price target of $610.00 to $590.00. The current price Chemed (CHE) is trading at is $514.14, which is out of the analyst's predicted range.